DoD Melanoma, Translational Research Award | W81XWH 19 MRP TRA

FAQs: DoD Melanoma Research Program (MRP) Translational Research Award (FY19)

What is this funding opportunity?

The Department of Defense (DoD) Melanoma Research Program (MRP) Translational Research Award (FY19) is a discretionary funding opportunity administered through USAMRAA (U.S. Army Medical Research Acquisition Activity). It supports hypothesis-driven, high-impact melanoma research that is mature and positioned to move toward real-world clinical use.

What is the main purpose of the Translational Research Award?

The purpose is to accelerate strong scientific findings toward practical melanoma treatment and/or prevention strategies. The program is oriented toward research that has a clear, credible path to clinical applicability rather than early exploratory studies that are still far from clinical relevance.

What does the program mean by “translational momentum”?

Translational momentum refers to continuity and readiness: the proposed work should clearly build on prior results, be supported by data, use rigorous methods, and focus on next steps that can reasonably move the project closer to clinical use (for example, influencing patient care, supporting clinical decisions, or accelerating interventions).

Is this award intended for early-stage exploratory research?

No. The solicitation emphasizes that it is not intended to support early exploratory work that is still far from clinical relevance. Projects should be mature and positioned for translation.

What kind of research is most competitive under this award?

Competitive projects are expected to be hypothesis-driven, high-impact, clinically relevant, and methodologically rigorous, with clear scientific outcomes and results that are usable for downstream development. Reviewers are expected to heavily weigh whether the work can influence clinical care or meaningfully advance translation.

How important is clinical relevance in review?

Clinical relevance is a major emphasis. Reviewers are expected to consider whether the project is positioned to affect patient care, inform clinical decision-making, or accelerate the development of interventions.

Does the program expect the use of human clinical samples?

Yes, meaningful use of clinical samples is strongly emphasized, especially samples derived from clinical trials and/or established biorepositories. The program favors work that connects mechanistic or biological insight to human melanoma in a direct and credible way.

Are projects based mainly on laboratory cell lines encouraged?

No. The opportunity indicates that applications built primarily around established cell lines fall outside the scope, particularly when used as the main basis for metastatic disease modeling.

Are late-stage disease models allowed?

The solicitation states the award is not intended to support studies centered on established late-stage disease models, including established macrometastatic disease.

Are metastatic disease models using established cell lines allowed?

No. The award specifically calls out models of metastatic disease that rely on established cell lines as outside the program’s intended scope.

Is research on PD-1 combinations responsive to this award?

The solicitation indicates the program is not requesting research focused on the clinical utility of PD-1 in combination with other therapeutics for this cycle, suggesting that direction is not aligned with FY19 priorities.

Can the project involve non-melanoma skin cancers?

No. Studies involving non-melanoma skin cancers are expressly disallowed under the FY19 MRP. The focus must remain strictly on melanoma.

Does the program prioritize broad relevance over narrow niche questions?

Yes. Applicants are encouraged to frame their work around commonalities in melanoma research that can advance broader understanding of the field, rather than narrow questions that would not generalize well.

What types of outcomes should the research aim to produce?

The program emphasizes clear scientific outcomes supported by robust experimental design, appropriate controls, and strong analytical approaches, with an emphasis on generating results that are usable for downstream development and potential clinical extension.

What funding mechanisms may be used for awards?

Funding may be provided through either a grant or a cooperative agreement, depending on the nature of the project and the level of involvement expected from the government.

What determines whether an award is a grant versus a cooperative agreement?

The summary indicates this depends on the project’s nature and the expected level of government involvement. More involvement typically aligns with a cooperative agreement, while less involvement aligns with a grant.

What is the opportunity number for this announcement?

The opportunity number is W81XWH 19 MRP TRA.

What CFDA program is associated with this opportunity?

This opportunity is listed under CFDA 12.420 (military medical research and development).

Who is eligible to apply?

Eligibility is listed as unrestricted, meaning a wide range of applicant entity types may apply, subject to any additional eligibility clarifications that may appear in the full announcement.

When was this opportunity posted?

The posting date is May 16, 2019.

What was the original closing date?

The original closing date is October 23, 2019.

How many awards are expected?

The forecasted number of awards is 2, indicating a small number of awards and a highly competitive program.

Is there a maximum award amount (ceiling)?

The listing shows an award ceiling of 0. This typically means the ceiling is not provided in that summary field and would need to be confirmed in the full funding announcement or related program documents.

What should applicants do if key details are missing from the summary listing?

Where the summary omits details (for example, the award ceiling), applicants should consult the full funding announcement and any associated program documents for authoritative requirements and limits.